Table 3

PRO response by clinical response* at week 52 (CZP 200 mg plus MTX group, ITT population)

ACR20 response by (%)


SF-36 PCS

SF-36 MCS

HAQ-DI

Pain

FAS

PtGA


Clinical response

No

Yes

No

Yes

No

Yes

No

Yes

No

Yes

No

Yes

PRO response

No

45.5

14.7

43.4

19.5

44.4

8.7

44.4

3.8

44.1

7.1

86.9

2.0

Yes

1.0

38.8

3.1

33.9

2.6

44.4

1.0

38.2

2.8

45.9

0

11.1

Tetrachoric correlation (ASE)

0.9450 (0.0178)

0.8389 (0.0356)

0.9504 (0.0152)

0.9804 (0.0076)

0.9574 (0.0135)

0.9996 (0.0053)

DAS response by (%)


SF-36 PCS

SF-36 MCS

HAQ-DI

Pain

FAS

PtGA


Clinical response

No

Yes

No

Yes

No

Yes

No

Yes

No

Yes

No

Yes

PRO response

No

44.2

16.5

43.2

20.4

43.6

10.0

43.6

5.1

43.9

7.7

44.1

4.9

Yes

1.0

38.2

2.1

34.4

2.1

44.4

2.1

49.2

1.8

46.7

1.5

49.5

Tetrachoric correlation (ASE)

0.9344 (0.0204)

0.8674 (0.0322)

0.9496 (0.0156)

0.9776 (0.0085)

0.9672 (0.0114)

0.9833 (0.0069)


*Clinical response = DAS or ACR20 response.

ACR20 = American College of Rheumatology 20% improvement; ASE = asymptomatic standard error; CZP = certolizumab pegol; DAS = disease activity score; FAS = fatigue assessment scale; HAQ-DI = health assessment questionnaire-disability index; ITT = intent to treat; MCS = mental component summary; MTX = methotrexate; PtGA = patient's global assessment; PCS = physical component summary; PRO = patient-reported outcomes; SF-36 = short-form 36-item health survey

Strand et al. Arthritis Research & Therapy 2009 11:R170   doi:10.1186/ar2859

Open Data